Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Annovis BioJohnson & Johnson
Last price
$0.99$255.56
Currency
USD
USD
$42M$616B
-38.81
-$1.79$6.58
1.240.21
0$5.28
02.10%
Sector
HealthHealth
Employees
-138,200
Ticker
$ANVS$JNJ
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ANVS or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.